Gainers
• Innovate, Inc. INNT stock rose 29.2% to $0.85 during Wednesday's after-market session.
• Genprex, Inc. GNPX stock surged 14.8% to $2.17.
• Alector, Inc. ALEC shares moved upwards by 11.2% to $25.50. The most recent rating by BTIG, on November 21, is at Buy, with a price target of $28.00.
• Ritter Pharmaceuticals, Inc. RTTR stock increased by 6.4% to $0.21.
• Sierra Oncology, Inc. SRRA shares moved upwards by 5.8% to $0.37. The most recent rating by Oppenheimer, on December 06, is at Outperform, with a price target of $1.20.
• Marinus Pharmaceuticals, Inc. MRNS shares rose 5.8% to $2.38. The most recent rating by H.C. Wainwright, on January 10, is at Buy, with a price target of $6.00.
• Achieve Life Sciences, Inc. ACHV shares surged 5.5% to $0.63.
• Unum Therapeutics, Inc. UMRX stock moved upwards by 5.0% to $1.25. The most recent rating by Morgan Stanley, on November 27, is at Overweight, with a price target of $3.00.
• Affimed, Inc. AFMD stock moved upwards by 4.5% to $3.03.
• Osmotica Pharmaceuticals, Inc. OSMT stock rose 4.3% to $6.99.
• Neurotrope, Inc. NTRP stock moved upwards by 4.2% to $1.48.
• MannKind, Inc. MNKD stock increased by 3.5% to $1.75. According to the most recent rating by Oppenheimer, on December 24, the current rating is at Outperform.
• Nektar Therapeutics, Inc. NKTR stock increased by 3.3% to $22.87. The most recent rating by JP Morgan, on November 13, is at Neutral, with a price target of $28.00.
• Oncolytics Biotech, Inc. ONCY stock increased by 3.3% to $3.46.
• Lexicon Pharmaceuticals, Inc. LXRX shares surged 3.2% to $3.89. According to the most recent rating by Gabelli & Co., on December 11, the current rating is at Hold.
• Baudax Bio, Inc. BXRX stock surged 3.2% to $8.80.
• Jaguar Health, Inc. JAGX shares surged 3.0% to $0.85. The most recent rating by H.C. Wainwright, on November 18, is at Buy, with a price target of $3.00.
Losers
• Tetraphase Pharmaceutical, Inc. TTPH shares fell 23.2% to $2.95 during Wednesday's after-market session. The most recent rating by Gabelli & Co., on October 31, is at Buy, with a price target of $5.00.
• Karuna Therapeutics, Inc. KRTX stock declined 12.1% to $101.35. The most recent rating by Wells Fargo, on January 22, is at Overweight, with a price target of $137.00.
• Dare Bioscience, Inc. DARE stock decreased by 11.8% to $1.50.
• Trillium Therapeutics, Inc. TRIL shares fell 10.6% to $2.92.
• Concert Pharmaceuticals, Inc. CNCE stock fell 5.3% to $12.40.
• Midatech Pharma, Inc. MTP stock decreased by 5.1% to $0.84.
• vTv Therapeutics, Inc. VTVT shares declined 3.5% to $2.50.
• Xenon Pharmaceuticals, Inc. XENE stock decreased by 3.5% to $16.25. According to the most recent rating by William Blair, on January 08, the current rating is at Outperform.
• Titan Pharmaceuticals, Inc. TTNP stock declined 3.3% to $0.32.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.